AEON Biopharma / Priveterra Acquisition Corp. — 2022 Form 10-K Summary
Reporting context: This is Priveterra Acquisition Corp.’s annual report for the year ended December 31, 2022, not an operating-company 10-K filed by AEON Biopharma. Priveterra was a blank-check company; at year-end it had signed an agreement to merge with AEON, but the transaction had not closed. The proposed merger would give AEON stockholders shares valued at an implied AEON equity value of $165 million, subject to transaction terms and closing conditions.
Key financial metrics
| Metric | 2022 | 2021 |
|---|---|---|
| Operating revenue | None | None |
| Operating costs / loss from operations | $3.33 million | $1.94 million |
| Net income | $9.98 million | $8.20 million |
| Interest income on trust investments | $3.71 million | $0.08 million |
| Net cash used in operating activities | $0.98 million | $1.49 million |
| Cash outside trust at year-end | $67,909 | $497,412 |
| Trust account at year-end | $279.38 million | $276.08 million |
| Current liabilities | $3.88 million | $0.83 million |
| Warrant liabilities | $0.67 million | $7.38 million |
| Deferred underwriting fee payable | $5.89 million | $9.66 million |
Net income was not generated by operating revenue: it principally reflected a $6.72 million non-cash gain from the decrease in warrant liabilities, $3.77 million of income from an underwriter’s fee waiver, and trust interest. Operating costs and an $0.88 million income-tax provision partly offset these items. No operating margins are meaningful for this pre-combination SPAC. The filing reports no operating-company debt; it does report a $150,000 non-interest-bearing related-party promissory note payable at combination or winding-up.
Material changes and subsequent events
- Versus 2021, operating costs increased, while trust interest rose substantially. Net income increased despite the operating loss, primarily because of warrant remeasurement, trust interest, and the underwriting-fee waiver.
- After year-end, stockholders approved extending the combination deadline to August 11, 2023. At the February 10, 2023 meeting, holders redeemed 25,597,728 public shares for approximately $258.79 million, leaving 2,002,272 public shares and a reported post-redemption trust balance of about $20.26 million.
- AEON’s closing condition required at least $45 million of available closing cash. The parties had interim financing letter agreements for $20 million, but the filing does not establish that the cash condition was ultimately satisfied.
- One underwriter waived $3.77 million of deferred fees in 2022; a second waived a further $4.64 million in January 2023. The year-end payable was $5.89 million before that later waiver.
Outlook, risks, contingencies, and unusual items
- The company had no operating business or revenue and reported substantial doubt about its ability to continue as a going concern, citing limited cash outside trust, a working-capital deficit, ongoing transaction costs, and the approaching combination deadline. If it failed to complete a combination by the deadline, it would have to wind up and redeem public shares, subject to creditor claims and other conditions.
- The AEON merger remained conditional on stockholder approvals, regulatory and listing requirements, effectiveness of the registration statement, minimum net tangible assets, and the available-cash condition. Completion was not assured.
- The merger agreement provided for up to 16 million additional shares to AEON stockholders upon specified clinical-development and FDA-review milestones. These contingent shares could materially dilute other holders if earned.
- After the special meeting, the trust balance reported in the filing was materially below the $45 million closing-cash condition before considering financing. Redemption-related excise tax under the Inflation Reduction Act could further reduce cash available, depending on transaction structure and applicable guidance.
- A shareholder lawsuit and related demand letters alleged that the merger registration statement omitted material information and sought corrective disclosures. The filing does not quantify a potential financial exposure.
- The company cited risks from dilution, transaction financing, potential creditor claims against trust assets, limited liquidity, and possible liquidation. Management reported effective disclosure controls and internal control over financial reporting; the auditor issued an unmodified opinion but included a going-concern explanatory paragraph.
Important facts for investors to verify
- Confirm the final post-redemption trust cash, financing proceeds, and whether the merger’s $45 million available-cash condition was met.
- Check the status and final terms of the AEON merger, including approvals, Nasdaq listing, registration effectiveness, and any amendments to consideration or milestone shares.
- Reconcile the underwriting-fee waiver figures: the disclosed $3.77 million and $4.64 million waivers total $8.40 million, while another filing passage describes total waivers of $8.69 million.
- Review the shareholder lawsuit and demand letters, including any settlement, corrective disclosures, or resulting costs.
- Verify share counts and redemption figures across the cover page, subsequent-event disclosures, and transaction documents, and assess dilution from founder shares, warrants, financing, and contingent consideration.